arbiter
JournalsPricingAccount

Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors

Jesse D. Ortendahl et al.

Journal of Medical Economics2026https://doi.org/10.1080/13696998.2026.2644108article
ABDC C
Weight
0.50

What the paper says

WES/WTS testing resulted in more patients directed to targeted therapies with a minimal budget impact and should be considered in clinical decision-making to improve patient outcomes.

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1080/13696998.2026.2644108

Or copy a formatted citation

@article{jesse2026,
  title        = {{Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors}},
  author       = {Jesse D. Ortendahl et al.},
  journal      = {Journal of Medical Economics},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1080/13696998.2026.2644108},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.